secwatch.observer — SEC 8-K summary
======================================

Issuer:     Erasca, Inc. (ERAS)
CIK:        0001761918
Form:       8-K
Filed at:   2023-08-29T23:59:59+00:00
Accession:  0000950170-23-045056
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Erasca doses first patient in Phase 1b SEACRAFT-1 trial of naporafenib plus trametinib for RAS Q61X tumors
--------------------------------------------------------------------------------

- SEACRAFT-1 evaluates pan-RAF inhibitor naporafenib + MEK inhibitor trametinib in RAS Q61X solid tumors; addressable patient population >150k in US/Europe.
- Signal-seeking efficacy data expected between Q2 and Q4 2024.
- Pivotal Phase 3 SEACRAFT-2 trial for NRAS-mutant melanoma on track to start H1 2024.
- Naporafenib licensed from Novartis; Erasca has not conducted prior clinical trials of the drug.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761918/000095017023045056/0000950170-23-045056-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761918/000095017023045056/eras-20230829.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-045056

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer